Here are the financial returns on generative AI investments at health systems, according to a Jan. 29 Deloitte report that surveyed 121 healthcare C-suite executives across the globe:
1. Too early to measure/haven’t measured: 37%
2. Moderate return on investment: 33%
3. Low return on investment: 12%
4. Significant return on investment: 10%
5. Did not invest enough to assess return: 5%
6. Not sure/can’t say: 2%
